Who are Sublingual Dexmedetomidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): treatment with brimonidine/timolol, lofexidine HCl, Combigan Two Times Daily (BID), Brimonidine ophthalmic solution 0.1%, Brimonidine 0.33%, brimonidine tartrate ophthalmic solution.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sublingual-dexmedetomidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sublingual Dexmedetomidine — Competitive Intelligence Brief

Sublingual Dexmedetomidine (Sublingual Dexmedetomidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Anesthesiology.

phase 3 Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Sublingual Dexmedetomidine (Sublingual Dexmedetomidine) — Nourhan M.Aly. Dexmedetomidine is an alpha-2 adrenergic agonist that acts as a sedative and anxiolytic.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sublingual Dexmedetomidine TARGET	Sublingual Dexmedetomidine	Nourhan M.Aly	phase 3	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
treatment with brimonidine/timolol	treatment with brimonidine/timolol	Aristotle University Of Thessaloniki	marketed	Alpha-2 adrenergic agonist / Beta-blocker combination	Alpha-2 adrenergic receptor; Beta-1 and Beta-2 adrenergic receptors
lofexidine HCl	lofexidine HCl	USWM, LLC (dba US WorldMeds)	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
Combigan Two Times Daily (BID)	Combigan Two Times Daily (BID)	Cornerstone Health Care, PA	marketed	Fixed-dose combination of alpha-2 adrenergic agonist and beta-blocker	Alpha-2 adrenergic receptor; beta-1 and beta-2 adrenergic receptors
Brimonidine ophthalmic solution 0.1%	Brimonidine ophthalmic solution 0.1%	Allergan	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor
Brimonidine 0.33%	Brimonidine 0.33%	Derm Research, PLLC	marketed	Alpha-2 adrenergic agonist	Alpha-2 adrenergic receptor
brimonidine tartrate ophthalmic solution	brimonidine tartrate ophthalmic solution	Allergan	marketed	Alpha-2 adrenergic receptor agonist	Alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

USWM, LLC (dba US WorldMeds) · 2 drugs in this class
China International Neuroscience Institution · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class
Eye Therapies, LLC · 1 drug in this class
Galderma R&D · 1 drug in this class
Guangzhou Women and Children's Medical Center · 1 drug in this class
Derm Research, PLLC · 1 drug in this class
Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class
American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sublingual Dexmedetomidine — Competitive Intelligence Brief. https://druglandscape.com/ci/sublingual-dexmedetomidine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab